The IDIAP Jordi Gol
Who we are
Organization
Quality Certification
Strategic plan
Annual reports
HRS4R
Transparency
Research
Territorial Support Units (USR)
Research Areas
Publications
Projects
CEIm
CEIM presentation
How to Submit the Documentation to the CEIM
Rates of The CEI
CEI meeting calendar
Regulations and links of interest CEI
Services and Platforms
AGICAP
Grants to Finance Research
Clinical Trial Monitoring
Platforms Questionnaires
Sidiap Database
Real World Lab
Tools-Help
Scientific Tools
Management Tools
IDIAP Management Tools
Innovation
News
Link GIR
Acces GIR
Login
Català
Castellano
English
The IDIAP Jordi Gol
Who we are
Organization
Quality Certification
Strategic plan
Annual reports
HRS4R
Transparency
Research
Territorial Support Units (USR)
Research Areas
Publications
Projects
CEIm
CEIM presentation
How to Submit the Documentation to the CEIM
Rates of The CEI
CEI meeting calendar
Regulations and links of interest CEI
Services and Platforms
AGICAP
Grants to Finance Research
Clinical Trial Monitoring
Platforms Questionnaires
Sidiap Database
Real World Lab
Tools-Help
Scientific Tools
Management Tools
IDIAP Management Tools
Innovation
News
Link GIR
Search
Most popular
COL·LABORA
Menu
English
Català
Español
Home
USR Barcelona
USR Barcelona
RESPONSABLE
Daniel Martínez Laguna
dmartinezl.bcn.ics@gencat.cat
Presentation
Team
Groups
Publications
Projects
News
Presentation
Team
Groups
Publications
Projects
News
Projects
Group projects
A phase III, double-blind, randomized, placebo and metformin-controlled clinical trial to evaluate the safety and efficacy of sitagliptin in pediatric patients with type 2 diabetes mellitus with inadequate glycemic control. MK-0431 (083-01)
Principal investigators:
Ernest Vinyoles Bargalló
Code:
9F13/009
Start year:
2013
Funders:
Merck Sharp & Dohme de España, S.A.
Estudio a 5 años para comparar la durabilidad de control glucémico de un régimen de combinación con vildagliptina y la metformina versus monoterapia con metformina como terapia estándar, iniciado en pacientes sin tratamiento previo con diabetes mellitus tipo 2, CLAF237A23156
Principal investigators:
Ernest Vinyoles Bargalló
Code:
9F13/013
Start year:
2013
Funders:
Novartis Farmacéutica, S.A.
Estudio longitudinal del control multifactorial de la diabetes tipo 2 e intensidad del tratamiento en Atención Primaria
Principal investigators:
Josep Franch Nadal
Code:
9F14/001
Start year:
2014
Funders:
AstraZeneca Farmacéutica Spain, S.A.
Preliminary Feasibility Study: A Randomized, Event Driven, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin on the Development of Type 2 Diabetes Mellitus (T2DM) in Subjects with prediabetes
Principal investigators:
Ernest Vinyoles Bargalló
Code:
9F16/001
Start year:
2016
Funders:
Janssen - Cilag, S.A.
Assaig Clínic HTA i danys substància gris. Estudi ISIS
Principal investigators:
Ernest Vinyoles Bargalló
Code:
9F17/002
Start year:
2017
Funders:
Institut d’Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol)
Anterior
1
…
208
209
210
211
Següent
Board of Trustees
Collaborators
Accreditations